Literature DB >> 10406987

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

S Orimo1, E Ozawa, S Nakade, T Sugimoto, H Mizusawa.   

Abstract

OBJECTIVES: (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy is clinically used to estimate local myocardial sympathetic nerve damage in some forms of heart disease, autonomic nerve disturbance in diabetic neuropathy, and disturbance of the autonomic nervous system in neurodegenerative disease. In the present study, examinations were performed to clarify (1) the proportion of cardiac sympathetic nerve disturbance in Parkinson's disease, (2) the usefulness of (123)I-MIBG myocardial scintigraphy to detect sympathetic nerve disturbances compared with autonomic function tests, (3) cardiac function in patients who have a decreased MIBG uptake in (123)I-MIBG myocardial scintigraphy, (4) the usefulness of (123)I-MIBG myocardial scintigraphy to differentiate Parkinson's disease from the other neurological diseases mimicking it.
METHODS: (123)I-MIBG myocardial scintigraphy was performed, together with autonomic function tests and cardiac examinations in 46 patients with Parkinson's disease and 25 patients with vascular parkinsonism, essential tremor, or multiple system atrophy.
RESULTS: In an anterior image study, the average count per pixel in heart to mediastinum (H/M) ratio decreased in 80% of the patients with Parkinson's disease in the early phase and 84% in the late phase. The mean H/M ratio in Parkinson's disease was significantly lower than that in controls and the other diseases. The H/M ratio tended to decrease with the disease progression. In almost half of the patients in Hoehn and Yahr stage I, the H/M ratio was already decreased. The sympathetic skin response in upper and lower limbs, head up tilt test, and coefficient of variation of R-R interval were abnormal in 17%, 31%, 30%, and 17% of the patients, respectively. All the patients with abnormal autonomic functions were in Hoehn and Yahr stage III, IV, or V. Echocardiography showed normal left ventricular function. Twenty four hour Holter electrocardiography detected no serious arrhythmias except for one patient with non-sustained ventricular tachycardia.
CONCLUSION: (123)I-MIBG myocardial scintigraphy might detect early disturbances of the sympathetic nervous system in Parkinson's disease and might give useful diagnostic information to differentiate vascular parkinsonism, essential tremor, and multiple system atrophy from Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10406987      PMCID: PMC1736461          DOI: 10.1136/jnnp.67.2.189

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  31 in total

1.  Sympathetic cardioneuropathy in dysautonomias.

Authors:  D S Goldstein; C Holmes; R O Cannon; G Eisenhofer; I J Kopin
Journal:  N Engl J Med       Date:  1997-03-06       Impact factor: 91.245

2.  Lateral horn cells in progressive autonomic failure.

Authors:  D R Oppenheimer
Journal:  J Neurol Sci       Date:  1980-06       Impact factor: 3.181

3.  [Total defect of metaiodobenzylguanidine (MIBG) imaging on heart in Parkinson's disease: assessment of cardiac sympathetic denervation].

Authors:  A Satoh; T Serita; M Tsujihata
Journal:  Nihon Rinsho       Date:  1997-01

4.  Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy.

Authors:  M Yoshita
Journal:  J Neurol Sci       Date:  1998-02-18       Impact factor: 3.181

5.  Critical analysis of the disability in Parkinson's disease.

Authors:  D D Webster
Journal:  Mod Treat       Date:  1968-03

6.  Ultrastructure of Lewy bodies in the stellate ganglion.

Authors:  L S Forno; R L Norville
Journal:  Acta Neuropathol       Date:  1976-03-30       Impact factor: 17.088

7.  Parkinson's disease: distribution of Lewy bodies and monoamine neuron system.

Authors:  E Ohama; F Ikuta
Journal:  Acta Neuropathol       Date:  1976-04-26       Impact factor: 17.088

Review 8.  Autonomic dysfunction in Parkinson's disease.

Authors:  Y Koike; A Takahashi
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

9.  The hypothalamus in Parkinson disease.

Authors:  J W Langston; L S Forno
Journal:  Ann Neurol       Date:  1978-02       Impact factor: 10.422

10.  Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine.

Authors:  D M Wieland; J Wu; L E Brown; T J Mangner; D P Swanson; W H Beierwaltes
Journal:  J Nucl Med       Date:  1980-04       Impact factor: 10.057

View more
  74 in total

Review 1.  Multiple system atrophy: pathophysiology and management.

Authors:  G K Wenning; S Braune
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Cardiac sympathetic neuroimaging to distinguish multiple system atrophy from Parkinson disease.

Authors:  D S Goldstein
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

Review 3.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

4.  Olfactory dysfunction and cardiovascular dysautonomia in Parkinson's disease.

Authors:  Hisayoshi Oka; Chizuko Toyoda; Makiko Yogo; Soichiro Mochio
Journal:  J Neurol       Date:  2010-01-30       Impact factor: 4.849

5.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

Review 6.  Early diagnosis of Parkinson's disease.

Authors:  Jörg Spiegel; Alexander Storch; Wolfgang H Jost
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

7.  Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease.

Authors:  Haruo Hanyu; Soichiro Shimizu; Kentaro Hirao; Hidekazu Kanetaka; Toshihiko Iwamoto; Taishiro Chikamori; Yasuhiro Usui; Akira Yamashina; Kiyoshi Koizumi; Kimihiko Abe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-11-22       Impact factor: 9.236

8.  Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease.

Authors:  K Hamada; M Hirayama; H Watanabe; R Kobayashi; H Ito; T Ieda; Y Koike; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

9.  Alpha-synuclein immunohistochemistry of gastrointestinal and biliary surgical specimens for diagnosis of Lewy body disease.

Authors:  Shinji Ito; Masaki Takao; Hiroyuki Hatsuta; Kazutomi Kanemaru; Tomio Arai; Yuko Saito; Masashi Fukayama; Shigeo Murayama
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

10.  3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease.

Authors:  Kimihiro Ogisu; Kohsuke Kudo; Makoto Sasaki; Ken Sakushima; Ichiro Yabe; Hidenao Sasaki; Satoshi Terae; Mitsuhiro Nakanishi; Hiroki Shirato
Journal:  Neuroradiology       Date:  2013-03-23       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.